Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 15/20 | 0.52 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP10 | P09238 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL6529639 | 0.85 | FKBP1A (0.41) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL26127986 | 0.76 | FKBP1A (0.66) | FKBP1A | |
| SCHEMBL5966234 | 0.76 | FKBP1A (0.66) | FKBP1A | |
| SCHEMBL26130649 | 0.76 | FKBP1A (0.66) | FKBP1A | |
| SCHEMBL5894483 | 0.76 | MMP8 (0.52) | FKBP1AMMP8MMP12MMP13MMP1 | |
| Hydroxyamine SCHEMBL5894442 | 0.75 | FKBP1A (0.50) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL6831371 | 0.73 | FKBP1A (0.54) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL6831374 | 0.73 | FKBP1A (0.54) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL27552135 | 0.72 | FKBP1A (0.47) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL4797076 | 0.72 | FKBP1A (0.65) | FKBP1AMMP8MMP12MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030242-B2 | Selective inhibition of aggrecanase in osteoarthritis treatment | PFIZER INC (US) | 2006-04-18 | — | — | US | disclosed |
| US-20050227997-A1 | 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction | NOE MARK C | 2005-10-13 | — | — | US | disclosed |
| EP-1081137-A1 | Selective inhibitors of aggrecanase in osteoarthritis treatment | Pfizer Products Inc. (US) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227997-A1 | 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction | MMP3, MMP1, MMP13 | FKBP1A 2344/4885MMP8 28/4885MMP12 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.